Last Update:
December 08, 2014
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
Pharmacokinetics Studies
| |
Lopinavir pharmacokinetic variability in a population of heavily treated
patients
C Torti, E Quiros-Roldan, S Di Giambenedetto, et al
Abstract
Pharmacokinetics of once-daily (QD)
lopinavir/ritonavir (LPV/r) as part of a regimen also
containing two nucleosides administered QD: the influence of dose
modifications.
DM Burger, CJL La Porte, EF Schippers, et al
Abstract |
|
Adolescent/Adult Treatment Studies
|
POSTER
Higher Doses of Lopinavir/ritonavir (LPV/r)
in Highly Treatment-Experienced, HIV-
Infected Patients:48-Week Safety/Efficacy Evaluation
D Podzamczer, R Tressler, C Flexner, et al
PDF
Poster
|
| |
POSTER
Single drug HAART (Lopinavir/r) for maintenance of HIV viral
suppression: Week 24
results of an open-label; pilot clinical trial-Only Kaletra OK Study
JR Arribas, F Pulido, A Lorenzo, et al
PDF
Poster
|
| |
POSTER
Lopinavir/ritonavir (LPV/r) Safety, Tolerability and Efficacy in
Hepatitis C and/or Hepatitis
B-infected Patients: Review of Clinical Trials
B da Silva, M King, P Cernohous, et al
PDF
Poster
|
|
POSTER
Maintenance Therapy Using
Lopinavir/Ritonavir (LPV/r) Alone for Patients With Well-
Controlled HIV-Infection
P. Ruane, A. Luber, C.
Gaultier, et al
PDF
Poster
|
|
POSTER
Simplification to
Lopinavir/Ritonavir Monotherapy from NNRTI-Based HAART in
HIV-Infected Patients With Complete Viral Suppression;24-Week
Interim Analysis
G. Pierone, J. Mieras, L. Fontaine, et al
PDF
Poster
Simplification to Lopinavir/r single-drug
HAART: 24 weeks results of a randomized,
controlled, open label, pilot clinical trial (OK Study)
JR Arribas, F Pulido, A Lorenzo, et al
Abstract
|
|
|
The LOPSAQ salvage study: 48
week analysis of the full cohort treated
with lopinavir (LPV/r) plus saquinavir (SQV) without any additional
antiretroviral (ART) therapy
S Staszewski, B
Dauer, A Carlebach, et al
Abstract |
|
|
|
Lopinavir/ritonavir- versus efavirenz-based therapy as
the two first-line HAART regimens
for naive HIV-infected subjects
R Manfredi, L Calza, F Chiodo
Abstract
Characteristics and initial virologic and Immunologic
data from the CLARE (CORE Center
Lopinavir/r Anti-retroviral Effectiveness) Cohort
OM Adeyemi, E Simeone, J Despotes, et al
Abstract
Higher doses of lopinavir/ritonavir (LPV/r) in
highly treatment-experienced, HIV-infected
patients: 48-week safety/efficacy evaluation
D Podzamczer, R Tressler, C Flexner, et al
Abstract
Lopinavir/ritonavir (LPV/r) and Saquinavir
hard gel (SQV) combination as alternative
HAART -regimen for HIV infected patients
V Frixon-Marin, C Solas, P Colson, et al
Abstract |
|
|
|
Pregnant Women/Neonate Studies
| |
Reduced
lopinavir exposure during pregnancy: preliminary pharmacokinetic
results from PACTG 1026
A Stek, M Mirochnick, E Capparelli, et al
Abstract
|
Pediatric Studies
|
| |
Kaletra (lopinavir/ritonavir) on treatment of HIV infected children
G Jugulete , M Mardarescu, S Petrea, et al
Abstract
Virological phenotype switches under salvage therapy
with lopinavir-ritonavir in
heavily pretreated HIV-1 vertically infected children
I Galán, MI De José, M L Navarro, et al
Abstract
Positive virologic outcome after
Lopinavir/ritonavir salvage therapy in protease
inhibitor-experienced HIV-1-infected children. A prospective
cohort study
S Resino, J M Bellón, I Galán, et al
Abstract |
|
|
Resistance Studies
| |
POSTER
Comprehensive Resistance Testing in
Antiretroviral-Naïve Patients Treated with
Once-Daily Lopinavir/ritonavir Plus Tenofovir DF and Emtricitabine:
48-Week Results
from Study 418
JM Molina, J Gathe, PL Lim, et al
PDF
Poster
Virological response and resistance to
Lopinavir/Ritonavir in non-B HIV-I patients
Z Grossman, M Lorber, E Shahar, et al
Abstract
Extensive resistance testing during 5 years of
lopinavir/ritonavir treatment in antiretroviral-naive
HIV infected patients: Results from study m97-720
C Hicks, B da Silva, C Benson, et al
Abstract |
|
|
Therapeutic Drug Monitoring Studies
| |
Dose changes, intrapatient
variability, and exposure to lopinavir (LPV) -
Implications for the use of therapeutic drug monitoring in the clinical
setting
CS Alexander, J
Montaner, J Asselin, et al
Abstract
Therapeutic drug monitoring (TDM) in patients taking
fosamprenavir & kaletra
as dual PI based antiretroviral therapy
C
Bell, A Hughes, K Asher, et al
Abstract
Therapeutic Drug monitoring (TDM) of
lopinavir/ritonavir (LPV/r) combination in Caribbean
HIV infected patients
A Cabié, C Lamotte, G Dos Santos, et al
Abstract |
|
|
|
KLS
Main Page